SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities

Diffuse large B-cell lymphomas (DLBCL) are genetically and phenotypically heterogeneous, making diagnosis and treatment challenging. Current models suggest DLBCL derive from follicular B cells engaged in adaptive immune responses. By studying co-occurring truncating mutations in SPEN and NOTCH2 in the BN2-DLBCL subtype, our data suggest a previously unrecognized extra-follicular trajectory. Using animal models and human specimens, we find this cooperative mutational axis supports expansion of putative clonal precursors with features of marginal zone, memory and a distinct, autoimmune B-cell-like state. This trajectory is associated with sex-biased outcomes: female patients and mice exhibit reduced survival compared to males in our cohorts. Further analysis links this disparity to enhanced X-chromosome-linked expression and functionality of toll-like receptor signaling. We show that IRAK inhibition represents a potential sex-specific therapeutic strategy in preclinical models. These findings support a distinct developmental origin for BN2-DLBCL and identify a high-risk female population with actionable targets for precision therapy.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2026-04-21
DOI
https://doi.org/10.1158/2159-8290.cd-25-1458
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities

Cem Meydan, Sravya Tumuluru, Darko Barišić, Martín A. Rivas et al.
Cancer Discovery
Lymphoma Diagnosis and Treatment
article

SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities

Cem Meydan, Sravya Tumuluru, Darko Barišić, Martín A. Rivas, Irem Isgor, Leandro Venturutti, Laura K. Hilton, Pengyan Fa, Benedikt W. Pelzer, Shenon Sethi, Ari Melnick, Kojo S.J. Elenitoba‐Johnson, Ceyda Durmaz, David W. Scott, Ahmet Doǧan, Xiang Wang, Kenneth B. Hoehn, Prasath Pararajalingam, Matt Teater, Ioannis Karagiannidis, Montserrat C. Anguera, Sonia Dębek, Eralda Salataj, Richard Pelzl, Alireza Karbalayghareh, Sanket Shah, Coraline Mlynarczyk, Amy Chadburn, Hannah M. Isles, Emma M. Welter, Ramon Massoni-Badosa, Jacob B. Geri, Christopher R. Chin, Ryan D. Morin, Min Xia, Christina S. Leslie, Christopher E. Mason, Wendy Béguelin, Kostiantyn Dreval, Amos Fong, Colin Burdette, Jessie Fielding, H Christian Reinhardt, Isaac M. Spiegel, Zhengming Chen, Zowie E. Searcy
article en

Abstract

Diffuse large B-cell lymphomas (DLBCL) are genetically and phenotypically heterogeneous, making diagnosis and treatment challenging. Current models suggest DLBCL derive from follicular B cells engaged in adaptive immune responses. By studying co-occurring truncating mutations in SPEN and NOTCH2 in the BN2-DLBCL subtype, our data suggest a previously unrecognized extra-follicular trajectory. Using animal models and human specimens, we find this cooperative mutational axis supports expansion of putative clonal precursors with features of marginal zone, memory and a distinct, autoimmune B-cell-like state. This trajectory is associated with sex-biased outcomes: female patients and mice exhibit reduced survival compared to males in our cohorts. Further analysis links this disparity to enhanced X-chromosome-linked expression and functionality of toll-like receptor signaling. We show that IRAK inhibition represents a potential sex-specific therapeutic strategy in preclinical models. These findings support a distinct developmental origin for BN2-DLBCL and identify a high-risk female population with actionable targets for precision therapy.

Cancer Discovery
Dartmouth College (US), BC Cancer Agency (CA), Memorial Sloan Kettering Cancer Center (US), University of British Columbia (CA), University of Miami (US), Simon Fraser University (CA), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Cornell University (US), Yale University (US), Essen University Hospital (DE), BC Cancer Foundation (CA), Canadian Centre for Applied Research in Cancer Control (CA), University of Pennsylvania (US), Philadelphia University (US)
Gender equality
Openalex Percentile: Top 17%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.